Exscientia plc
Recent developments in the Company’s pipeline, collaborations, and operations as well as financial results for the fourth quarter and full year 2022 are summarised below.. | March 23, 2023
Precision designed LSD1 and MALT1 inhibitors currently progressing through IND-enabling studies Both molecules demonstrate Exscientia's ability to overcome critical design challenges and identify
Partnership will further validate Exscientia's functional drug testing platform to predict response in haematological cancers - Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with
Radio Astronomers Discover New Supernova Remnants in Milky Way Galaxy sci.news - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sci.news Daily Mail and Mail on Sunday newspapers.